Hexavest’s PTC Therapeutics PTCT Stock Holding History

Hexavest’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-8,457	Closed	-$357K	–	288
2021 Q2	$357K	Hold	8,457	–	–	0.02%	226
2021 Q1	$400K	Sell	8,457 -2,680	-24%	-$159K	0.02%	230
2020 Q4	$680K	Buy	+11,137	New	+$656K	0.03%	195

Other funds holding PTCT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Hexavest's PTCT Position: Q3 2021 in Review

Hexavest sold out of PTC Therapeutics (PTCT) in Q3 2021, closing a stake of 8,457 shares — an estimated $357K sold.

Hexavest first reported a position in PTCT in Q4 2020 and held it in 3 quarters. The position peaked at $680K in Q4 2020. 183 funds tracked by Wall St. Rank hold PTCT as of Q3 2021.

Hexavest reported no remaining PTC Therapeutics position as of Q3 2021 after selling out during the quarter.
Hexavest sold 8,457 PTC Therapeutics shares in Q3 2021, an estimated $357K.
Hexavest first reported a position in PTC Therapeutics in Q4 2020 and held it in 3 quarters.
Hexavest's PTC Therapeutics position peaked at $680K in Q4 2020.
183 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2021.

Based on Hexavest's 13F filing for Q3 2021, filed 27 Oct 2021.